H1N1 Influenza-A Virus New Caledonia/20/99 IVR 116


Product Specifications

50 ug or 1 mg
Sterile Filtered colorless solution FormulationThe H1N1 A/New Caledonia/20/99 IVR solution contains STE, 0.1 % sodium azide (NaN3) and 0.005 % thimerosal.
Greater than 90.0% as determined by ELISA analysis.
Recommended Applications:
Tested with anti-influenza A monoclonal antibodies in ELISA.Serological studies of influenza A virus, immunogen for antibody production.


Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza A virus, strain A/ New Caledonia/20/99 IVR 116. The Influenza Virus was purified by Ultracentrifugation with 10-40 % sucrose gradient.


Thimerosal and beta propiolactone treatment. This product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work.

Stability & Storage

A/New Caledonia/20/99 IVR although stable 4°C for 4 weeks, should be stored desiccated below -18°C. Please prevent freeze-thaw cycles.

No posts found

Write A Review
U.S. Non-U.S.


This product is furnished for LABORATORY RESEARCH USE ONLY.
Not for diagnostic or therapeutic use.